[EN] MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS<br/>[FR] PYRRAZOLES FUSIONNÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE MCL-1
申请人:ASCENTAGE PHARMA SUZHOU CO LTD
公开号:WO2020151738A1
公开(公告)日:2020-07-30
Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R 1a, R 1b, L 1, L 2, L 3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
提供由化学式IA表示的化合物,以及其在药学上可接受的盐和溶剂化合物,其中R、R 1a、R 1b、L 1、L 2、L 3、X、A、B和C的定义如规范中所述。还提供了化学式IA的化合物,用于治疗对Mcl-1抑制敏感的疾病或紊乱,如癌症。